Altimmune to Announce 12-Week Data From ALT-801 Phase 1 Trial on September 28, 2021

Rhea-AI Summary

Altimmune, Inc. (Nasdaq: ALT) announced the upcoming results of its 12-week Phase 1 clinical trial for ALT-801, aimed at treating obesity, to be released on September 28, 2021. The company will provide details during a conference call and webcast at 8:30 AM ET, which will also be available for replay on its website. This trial represents a significant step in Altimmune's development pipeline focused on obesity and liver diseases, part of its broader strategy to advance next-generation therapeutics.

Positive

• Upcoming release of Phase 1 clinical trial results for ALT-801, indicating progress in drug development.
• Focus on obesity and liver disease therapies, highlighting the company's strategic direction.

Negative

• None.

GAITHERSBURG, Md., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report the results from its 12-week Phase 1 clinical trial of ALT-801 in overweight and obese subjects in a pre-market press release and webcast to be held on Tuesday, September 28, 2021.

Altimmune management will host a conference call and webcast with a slide presentation beginning at 8:30 am E.T. Following the conclusion of the call, the webcast will be available for replay on the Investor Relations page of the Company’s website at www.altimmune.com. The company has used, and intends to continue to use, the IR portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.

Conference Call Information:

Date:	Tuesday, September 28
Time:	8:30 am Eastern Time
Domestic Dial-in:	(844) 615-6509
International Dial-in:	(918) 922-3148
Conference ID:	3792068
Webcast:	https://edge.media-server.com/mmc/p/ojyxaxpp

About Altimmune
Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Our pipeline includes next generation peptide therapeutics for obesity, NASH (ALT-801), and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Investor and Media Contact:
Will Brown
Chief Financial Officer
Phone: 240-654-1450
wbrown@altimmune.com

FAQ

What results will Altimmune report on September 28, 2021?

Altimmune will report the results of its 12-week Phase 1 clinical trial of ALT-801, focused on overweight and obese subjects.

What time will Altimmune's conference call take place?

The conference call will take place at 8:30 AM Eastern Time on September 28, 2021.

How can I access the webcast for Altimmune's trial results?

The webcast will be available on Altimmune's Investor Relations page and can also be accessed via a provided link during the conference call.

What is the significance of ALT-801 for Altimmune?

ALT-801 is part of Altimmune's efforts to develop treatments for obesity and liver diseases, representing key advancements in their therapeutic pipeline.